Therefore, improving the pharmacokinetic properties of HK inhibitors, prolonging the half-life of the drug, synthesizing novel analogs or prodrugs of HK inhibitors, and enhancing the targeting of such drugs to cancer cells in vivo to reduce the occurrence of adverse effects may be essential strategies to break the limits of clinical application. The gene discussed is HK1; the disease is cancer.